KEGG   DRUG: Empagliflozin and linagliptin
Entry
D10588            Mixture   Drug                                   

Name
Empagliflozin and linagliptin;
Glyxambi (TN)
Product
Component
Empagliflozin [DR:D10459], Linagliptin [DR:D09566]
Remark
Therapeutic category: 3969
ATC code: A10BD19
Product: D10588<JP/US>
Efficacy
Antidiabetic
  Disease
Type 2 diabetes mellitus [DS:H00409]
Comment
Empagliflozin is a substrate for P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP).
Metabolism
Transporter: ABCB1 [HSA:5243], ABCG2 [HSA:9429]
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 A ALIMENTARY TRACT AND METABOLISM
  A10 DRUGS USED IN DIABETES
   A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
    A10BD Combinations of oral blood glucose lowering drugs
     A10BD19 Linagliptin and empagliflozin
      D10588  Empagliflozin and linagliptin <JP/US>
USP drug classification [BR:br08302]
 Blood Glucose Regulators
  Antidiabetic Combinations
   Empagliflozin/ Linagliptin
    D10588  Empagliflozin and linagliptin
Therapeutic category of drugs in Japan [BR:br08301]
 3  Agents affecting metabolism
  39  Other agents affecting metabolism
   396  Antidiabetic agents
    3969  Others
     D10588  Empagliflozin and linagliptin
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10588
Drug metabolizing enzymes and transporters [br08309.html]
 Drug transporters
  D10588
Other DBs
PubChem: 254741550
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system